Artiva Biotherapeutics, Inc.
ARTV- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817241
In the last 90 days, Artiva Biotherapeutics, Inc. insiders filed 5 open-market purchases and 7 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $391.6M in total; Viking Global Investors is the only superinvestor holding it.
Holders of 5% or more of ARTV
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Artiva Biotherapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D/A | 37.90%18.4M shares | +1.30 ppfrom 36.60% | May 13, 20263 filings | Jul 23, 2026 | SEC |
| GC Corp. | 13D/A | 12.30%6.00M shares | – | May 28, 20261 filing | May 28, 2026 | SEC |
| Viking Global Investors LPSuperinvestorViking Global Investors | 13G | 5.40%2.60M shares | New | May 18, 20261 filing | May 18, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
10 Schedule 13D and 13G filings on Artiva Biotherapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20264:49 PM ET | Venrock Healthcare Capital Partners III, L.P.and 6 others | 13G/A | 4.20%2.04M shares | –Below 5% | Jun 30, 2026 | SEC |
| Aug 10, 20267:49 PM ET | 5AM Ventures VI, L.P.and 5 others | 13G/A | 4.80%2.35M shares | –Below 5% | Jun 30, 2026 | SEC |
| Jul 23, 20269:23 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 37.90%18.4M shares | +1.30 ppfrom 36.60% | Jul 22, 2026 | SEC |
| Jun 15, 20267:37 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 36.60%17.8M shares | +2.90 ppfrom 33.70% | Jun 11, 2026 | SEC |
| May 28, 20264:38 PM ET | GC Corp.and 2 others | 13D/A | 12.30%6.00M shares | – | May 11, 2026 | SEC |
| May 18, 20267:31 PM ET | Viking Global Investors LPand 9 othersSuperinvestorViking Global Investors | 13G | 5.40%2.60M shares | New | May 11, 2026 | SEC |
| May 13, 20265:47 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 33.70%16.4M shares | – | May 11, 2026 | SEC |
| Jul 16, 20257:02 PM ET | BlackRock, Inc. | 13G/A | 2.00%485.7K shares | −3.10 ppfrom 5.10%Below 5% | Jun 30, 2025 | SEC |
| May 15, 20254:44 PM ET | venBio Global Strategic Fund III, L.P.and 4 others | 13G/A | 4.90%1.20M shares | –Below 5% | Mar 31, 2025 | SEC |
| Apr 23, 20258:14 PM ET | BlackRock, Inc. | 13G | 5.10%1.25M shares | New | Mar 31, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Artiva Biotherapeutics, Inc. shares.
No Form 144 notices for Artiva Biotherapeutics, Inc. are on file.